KALA

SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 3

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,576 shares

Expires 2025-09-11

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F5 · derivative.exercise_date: The canceled option was granted on September 15, 2015 and provided for vesting over four years with 25% of the shares underlying the option vested on April 8, 2016 and 1/48th of the shares vested at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 2

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,449 shares

Expires 2025-06-03

F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F4 · derivative.exercise_date: The canceled option was granted on June 4, 2015 and provided for vesting over four years with 1/48th of the shares underlying the option vested on May 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter.

F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · nonDerivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,681

F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock.

F2 · balance_after: Includes 113,922 unvested RSUs.

SEC source: 0001415889-23-004976 · form4-03152023_080310.xml · derivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432

Underlying: Common Stock · 432 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option.

SEC source: 0001415889-23-004977 · form4-03152023_080312.xml · derivative · entry 1

Trachtenberg Eric · CIK 0001646300 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432

Underlying: Common Stock · 432 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option.

SEC source: 0001415889-23-004978 · form4-03152023_080315.xml · derivative · entry 1

Kharabi Darius · CIK 0001893729 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432

Underlying: Common Stock · 432 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option.

SEC source: 0001415889-23-004975 · form4-03152023_080306.xml · derivative · entry 1

Brazzell Romulus K · CIK 0001298079 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 576

Underlying: Common Stock · 576 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 2,160 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 576 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 432 shares of common stock underlying the option.

SEC source: 0001415889-23-004974 · form4-03152023_080304.xml · derivative · entry 1

Bazemore Todd · CIK 0001605767 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 576

Underlying: Common Stock · 576 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 2,160 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 576 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 432 shares of common stock underlying the option.

SEC source: 0001415889-23-004973 · form4-03152023_080301.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,512

Underlying: Common Stock · 1,512 shares

Expires 2032-01-03

F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 5,670 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters.

F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 1,512 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 1,134 shares of common stock underlying the option.

SEC source: 0001415889-23-009138 · form4-06022023_080624.xml · nonDerivative · entry 2

Kharabi Darius · CIK 0001893729 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,407

F3 · shares: The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the issuer issued 6,977 shares of the Issuer's common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023. This transaction is being reported late due to an inadvertent administrative error.

F3 · price: The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the issuer issued 6,977 shares of the Issuer's common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023. This transaction is being reported late due to an inadvertent administrative error.

F2 · balance_after: Includes 9,525 unvested RSUs.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 7

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,276

F10 · shares: On March 10, 2023, the Issuer issued 497 shares of its common stock to Garland Investments, L.P. ("Garland") as a result of the Dosing Milestone.

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F10 · price: On March 10, 2023, the Issuer issued 497 shares of its common stock to Garland Investments, L.P. ("Garland") as a result of the Dosing Milestone.

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F9 · ownership.nature: These securities are held directly by Garland. The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 5

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 168,454

F8 · shares: On March 10, 2023, the Issuer issued 65,634 shares of its common stock to Lagunita Biosciences, LLC ("Lagunita") as a result of the Dosing Milestone.

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F8 · price: On March 10, 2023, the Issuer issued 65,634 shares of its common stock to Lagunita Biosciences, LLC ("Lagunita") as a result of the Dosing Milestone.

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F7 · ownership.nature: These securities are held directly by Lagunita. The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 2

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,167

F4 · shares: The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the Issuer issued 2,013 shares of its common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023 (the "Dosing Milestone").

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F4 · price: The purchase price in connection with the Acquisition included potential future payments that are contingent upon the achievement of specified development, regulatory and commercialization milestones. On March 10, 2023, the Issuer issued 2,013 shares of its common stock to the reporting person following achievement of a milestone related to dosing of the first patient in the Issuer's CHASE Phase 2b clinical trial of KPI-012 for PCED in the United States in February 2023 (the "Dosing Milestone").

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 6

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 779

F1 · kind: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F1 · price: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F9 · ownership.nature: These securities are held directly by Garland. The reporting person is a managing partner of Garland and may be deemed to have beneficial ownership over the Garland Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 4

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 102,820

F1 · kind: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F1 · price: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

F7 · ownership.nature: These securities are held directly by Lagunita. The reporting person is a managing partner of Lagunita and may be deemed to have beneficial ownership over the Lagunita Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-23-009139 · form4-06022023_080630.xml · nonDerivative · entry 1

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,154

F1 · kind: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F1 · price: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement.

F2 · price: This transaction is being reported late due to an inadvertent administrative error.

F3 · balance_after: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-000639 · form4-01062023_080117.xml · nonDerivative · entry 2

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,883

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 9,676 unvested RSUs.

SEC source: 0001415889-23-000639 · form4-01062023_080117.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,943

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 9,827 unvested RSUs.

SEC source: 0001415889-23-000640 · form4-01062023_080122.xml · nonDerivative · entry 2

Trachtenberg Eric · CIK 0001646300 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,495

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.79, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 9,676 unvested RSUs.

SEC source: 0001415889-23-000640 · form4-01062023_080122.xml · nonDerivative · entry 1

Trachtenberg Eric · CIK 0001646300 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,555

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 9,827 unvested RSUs.

SEC source: 0001415889-23-000641 · form4-01062023_080127.xml · nonDerivative · entry 1

Kharabi Darius · CIK 0001893729 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,439

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 9,525 unvested RSUs and 1,294 shares of the Issuer's common stock issuable to the Reporting Person in connection with the Issuer's acquisition of Combangio, Inc. and which are being held back by the Issuer until February 15, 2023 as partial security for the satisfaction of indemnification obligations and other payment obligations of the former Combangio equityholders.

F3 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-23-000638 · form4-01062023_080112.xml · nonDerivative · entry 2

Brazzell Romulus K · CIK 0001298079 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,536

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.59, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 12,984 unvested RSUs.

SEC source: 0001415889-23-000638 · form4-01062023_080112.xml · nonDerivative · entry 1

Brazzell Romulus K · CIK 0001298079 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,609

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 13,167 unvested RSUs.

SEC source: 0001415889-23-000637 · form4-01062023_080107.xml · nonDerivative · entry 2

Bazemore Todd · CIK 0001605767 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,835

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.73, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 12,984 unvested RSUs.

SEC source: 0001415889-23-000637 · form4-01062023_080107.xml · nonDerivative · entry 1

Bazemore Todd · CIK 0001605767 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,897

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 13,167 unvested RSUs.

SEC source: 0001415889-23-000636 · form4-01062023_080102.xml · nonDerivative · entry 2

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,966

F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5 · balance_after: Includes 42,207 unvested RSUs.

SEC source: 0001415889-23-000636 · form4-01062023_080102.xml · nonDerivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,164

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2 · balance_after: Includes 42,714 unvested RSUs.

SEC source: 0001415889-22-010936 · form4-11012022_011127.xml · derivative · entry 1

Farid Marjan · CIK 0001952098 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600

Underlying: Common Stock · 1,600 shares

Expires 2032-10-30

F1 · derivative.exercise_date: This option was granted on October 31, 2022 and vests with respect to 1/3rd of the shares underlying the option on October 31, 2023 and as to an additional 1/36th of the shares underlying the option at the end of each successive one-month period thereafter until October 31, 2025.

SEC source: 0001415889-22-010880 · form4-10282022_041020.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,418

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 302 unvested RSUs.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-22-010882 · form4-10282022_041033.xml · nonDerivative · entry 1

Trachtenberg Eric · CIK 0001646300 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,030

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.62, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 302 unvested RSUs.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-22-010881 · form4-10282022_041026.xml · nonDerivative · entry 1

Bazemore Todd · CIK 0001605767 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,097

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 367 unvested RSUs.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-22-010879 · form4-10282022_041008.xml · nonDerivative · entry 1

Brazzell Romulus K · CIK 0001298079 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,809

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.59, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 367 unvested RSUs and 365 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 30, 2022.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-22-010878 · form4-10282022_041001.xml · nonDerivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,464

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.62, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 1,014 unvested RSUs.

F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.

SEC source: 0001415889-22-007062 · form4-06292022_050657.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,595

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 45,611 unvested RSUs.

SEC source: 0001415889-22-007063 · form4-06292022_050647.xml · nonDerivative · entry 1

Trachtenberg Eric · CIK 0001646300 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,203

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 45,611 unvested RSUs.

SEC source: 0001415889-22-007061 · form4-06292022_050657.xml · nonDerivative · entry 1

Brazzell Romulus K · CIK 0001298079 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 285,201

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 58,834 unvested RSUs.

SEC source: 0001415889-22-007060 · form4-06292022_050608.xml · nonDerivative · entry 1

Bazemore Todd · CIK 0001605767 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,499

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 58,834 unvested RSUs.

SEC source: 0001415889-22-007059 · form4-06292022_050622.xml · nonDerivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,183

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2 · balance_after: Includes 139,819 unvested RSUs.

SEC source: 0001415889-22-006754 · form4-06172022_040632.xml · derivative · entry 1

Myers C. Daniel · CIK 0001489533 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001415889-22-006752 · form4-06172022_040618.xml · derivative · entry 1

Rosen Howard B · CIK 0001307068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001415889-22-006753 · form4-06172022_040626.xml · derivative · entry 1

Blumenkranz Mark S. · CIK 0001614869 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001415889-22-006751 · form4-06172022_040613.xml · derivative · entry 1

PERRY GREGORY D · CIK 0001236371 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001415889-22-006750 · form4-06172022_040606.xml · derivative · entry 1

Paull Robert Bradley · CIK 0001711254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001415889-22-006749 · form4-06172022_040601.xml · derivative · entry 1

KOVEN ANDREW I · CIK 0001258673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.

SEC source: 0001104659-22-065351 · tm2216932-2_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 7,039,613

F1 · price: This transaction was executed in multiple trades at prices ranging from $0.35 to $0.3875; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F2 · balance_after: These securities include 7,039,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: These securities include 7,039,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-064706 · tm2216932-1_4.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,045,299

F5 · price: This transaction was executed in multiple trades at prices ranging from $0.40 to $0.52; the price reported above reflects the weighted average sale price.

F6 · balance_after: These securities include 8,045,299 shares held directly by the Fund.

F6 · ownership.nature: These securities include 8,045,299 shares held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-064706 · tm2216932-1_4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,479,808

F3 · price: This transaction was executed in multiple trades at prices ranging from $0.50 to $0.55, the price reported above reflects the weighted average sale price.

F4 · balance_after: These securities include 9,479,808 shares held directly by the Fund.

F4 · ownership.nature: These securities include 9,479,808 shares held directly by the Fund.

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-22-064706 · tm2216932-1_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,624,613

F1 · price: This transaction was executed in multiple trades at prices ranging from $0.60 to $0.72; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F2 · balance_after: These securities include 9,624,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: These securities include 9,624,613 shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F7 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-23-009138 · form4-06022023_080624.xml · nonDerivative · entry 1

Kharabi Darius · CIK 0001893729 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,430

F1 · kind: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement. This transaction is being reported late due to an inadvertent administrative error.

F1 · price: On November 15, 2021, the Issuer acquired Combangio, Inc. (the "Acquisition"). The disposition represented shares previously reported as acquired in the Acquisition that were forfeited in satisfaction of payment obligations of the former Combangio equityholders pursuant to the merger agreement. This transaction is being reported late due to an inadvertent administrative error.

F2 · balance_after: Includes 9,525 unvested RSUs.

SEC source: 0001415889-22-000405 · form4-01052022_080127.xml · nonDerivative · entry 1

Reumuth Mary · CIK 0001710969 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,208

F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F3 · balance_after: Includes 53,611 unvested RSUs.